Nalaganje...

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance

Although high rates of complete hematologic and cytogenetic remission have been observed in patients with chronic phase chronic myeloid leukemia (CML) treated with imatinib, a short duration of response with eventual emergence of imatinib resistance has also been reported in a subset of CML patients...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Martinelli, Giovanni, Iacobucci, Ilaria, Soverini, Simona, Palandri, Francesca, Castagnetti, Fausto, Rosti, Gianantonio, Baccarani, Michele
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2007
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2721303/
https://ncbi.nlm.nih.gov/pubmed/19707322
Oznake: Označite
Brez oznak, prvi označite!